Published in Br J Clin Pharmacol on December 01, 2009
Anti-obesity drugs: past, present and future. Dis Model Mech (2012) 1.36
Sibutramine on cardiovascular outcome. Diabetes Care (2011) 0.94
Rhein Reduces Fat Weight in db/db Mouse and Prevents Diet-Induced Obesity in C57Bl/6 Mouse through the Inhibition of PPARγ Signaling. PPAR Res (2012) 0.90
The utility of animal models to evaluate novel anti-obesity agents. Br J Pharmacol (2011) 0.88
Combination of the sodium-glucose cotransporter-2 inhibitor empagliflozin with orlistat or sibutramine further improves the body-weight reduction and glucose homeostasis of obese rats fed a cafeteria diet. Diabetes Metab Syndr Obes (2014) 0.86
Pharmacotherapy for childhood obesity: present and future prospects. Int J Obes (Lond) (2012) 0.83
Characterization of the 5-HT2C receptor agonist lorcaserin on efficacy and safety measures in a rat model of diet-induced obesity. Pharmacol Res Perspect (2014) 0.82
Central and peripheral molecular targets for antiobesity pharmacotherapy. Clin Pharmacol Ther (2010) 0.82
The Challenges and Opportunities Associated with Reimbursement for Obesity Pharmacotherapy in the USA. Pharmacoeconomics (2015) 0.79
Acute behavioural effects of bupropion and naltrexone, alone and in combination, in non-deprived male rats presented with palatable mash. Psychopharmacology (Berl) (2013) 0.76
Developing therapies for the metabolic syndrome: challenges, opportunities, and… the unknown. Ther Adv Endocrinol Metab (2010) 0.75
Silymarin Ameliorates Metabolic Dysfunction Associated with Diet-Induced Obesity via Activation of Farnesyl X Receptor. Front Pharmacol (2016) 0.75
Obesity: Current and potential pharmacotherapeutics and targets. Pharmacol Ther (2016) 0.75
Editorial for BJCP Special Obesity Edition. Br J Clin Pharmacol (2009) 0.75
The metabolic syndrome: what's in a name? Ther Adv Endocrinol Metab (2010) 0.75
Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation (2002) 76.93
Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med (1998) 46.95
Banting lecture 1988. Role of insulin resistance in human disease. Diabetes (1988) 33.22
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ (1998) 32.73
Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med (1995) 28.35
Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA (2003) 25.44
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med (2006) 19.09
Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med (2007) 18.45
Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med (2004) 17.91
Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N Engl J Med (2006) 16.17
The continuing epidemics of obesity and diabetes in the United States. JAMA (2001) 14.84
The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care (2005) 11.91
Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med (1996) 11.76
Cause-specific excess deaths associated with underweight, overweight, and obesity. JAMA (2007) 11.50
Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med (1997) 9.36
Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA (2002) 8.81
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care (2004) 6.64
Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet (2006) 6.50
Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk (1996) 6.18
Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care (2005) 5.77
Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med (2005) 5.38
XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care (2004) 5.34
Obesity in Britain: gluttony or sloth? BMJ (1995) 5.22
Association between obesity and psychiatric disorders in the US adult population. Arch Gen Psychiatry (2006) 5.06
Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care (2006) 4.91
Weight as a risk factor for clinical diabetes in women. Am J Epidemiol (1990) 4.64
The metabolic syndrome: is this diagnosis necessary? Am J Clin Nutr (2006) 4.35
A prospective study of the role of depression in the development and persistence of adolescent obesity. Pediatrics (2002) 4.14
Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ (2007) 3.99
The consequences of childhood overweight and obesity. Future Child (2006) 3.76
Obesity prevention: the case for action. Int J Obes Relat Metab Disord (2002) 3.56
Blood pressure reduction and secondary prevention of stroke and other vascular events: a systematic review. Stroke (2003) 3.41
The influence of food portion size and energy density on energy intake: implications for weight management. Am J Clin Nutr (2005) 3.20
The obesity epidemic: pathophysiology and consequences of obesity. Obes Res (2002) 3.04
Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care (2007) 3.02
Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Diabetes Care (2003) 2.82
Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial. Eur Heart J (2007) 2.56
Lowering blood pressure to prevent myocardial infarction and stroke: a new preventive strategy. Health Technol Assess (2003) 2.44
Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S) Circulation (1998) 2.40
Swedish obese subjects (SOS)--an intervention study of obesity. Two-year follow-up of health-related quality of life (HRQL) and eating behavior after gastric surgery for severe obesity. Int J Obes Relat Metab Disord (1998) 2.11
A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care (2001) 2.10
Primary pulmonary hypertension and fenfluramine use. Br Heart J (1993) 2.02
Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study. Am Heart J (2005) 1.96
Effect of metformin in pediatric patients with type 2 diabetes: a randomized controlled trial. Diabetes Care (2002) 1.88
Lipids and risk of coronary heart disease. The Framingham Study. Ann Epidemiol (1994) 1.86
Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) Project. Circulation (2001) 1.78
Epidemiology of triglycerides: a view from Framingham. Am J Cardiol (1992) 1.71
Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J (2003) 1.68
Two-year outcome of a combination of weight loss therapies for type 2 diabetes. Diabetes Care (2005) 1.68
Obesity: the disease of the twenty-first century. Int J Obes Relat Metab Disord (2002) 1.66
Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine. JAMA (2000) 1.64
Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care (1998) 1.58
Risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes: UKPDS 66. Diabetes Care (2004) 1.51
Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab (2001) 1.49
Effects of sibutramine on body weight and serum lipids: a double-blind, randomized, placebo-controlled study in 322 overweight and obese patients with dyslipidemia. Am Heart J (2001) 1.43
Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I. Am J Cardiol (1997) 1.36
Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial. Diabetes Care (2002) 1.35
Overeating among adolescents: prevalence and associations with weight-related characteristics and psychological health. Pediatrics (2003) 1.32
Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials. Int J Obes Relat Metab Disord (2002) 1.29
Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes. J Clin Endocrinol Metab (2003) 1.26
Body weight and mortality among adults who never smoked. Am J Epidemiol (1999) 1.21
Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care (2002) 1.18
Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. Diabetes Care (2000) 1.12
Behavioral satiety sequence (BSS) for the diagnosis of drug action on food intake. Pharmacol Biochem Behav (1998) 1.12
Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes Care (2001) 1.12
Sibutramine: a novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from d-amphetamine and d-fenfluramine. Int J Obes Relat Metab Disord (1998) 1.10
Age of onset and body dissatisfaction in obesity. Addict Behav (2002) 1.10
Pathophysiology of dyslipidaemia in the metabolic syndrome. Postgrad Med J (2005) 1.10
Prevention of hypertension and its complications: theoretical basis and guidelines for treatment. J Am Soc Nephrol (2003) 1.09
The antiatherogenic role of high-density lipoprotein cholesterol. Am J Cardiol (1998) 1.09
The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study. Int J Obes Relat Metab Disord (2001) 1.06
Pathways from obesity to hypertension: from the perspective of a vicious triangle. Int J Obes Relat Metab Disord (2002) 1.04
Metabolic syndrome and vascular disease: is nature or nurture leading the new epidemic of cardiovascular disease? Circulation (2004) 1.02
Orlistat. Drugs (1998) 0.99
Obesity: new perspectives and pharmacotherapies. Cardiol Rev (2006) 0.95
A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin. Diabetes Care (2003) 0.93
Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study. Curr Med Res Opin (2005) 0.92
Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analyses of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care (2004) 0.92
The effects of sibutramine on the microstructure of eating behaviour and energy expenditure in obese women. J Psychopharmacol (2008) 0.89
Cannabinoids and the regulation of ingestive behaviour. Curr Drug Targets (2005) 0.89
The effects of pharmacologic agents for type 2 diabetes mellitus on body weight. Postgrad Med (2008) 0.88
Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial. Clin Ther (2004) 0.86
Effect of orlistat added to diet (30% of calories from fat) on plasma lipids, glucose, and insulin in obese patients with hypercholesterolemia. Am J Cardiol (2003) 0.84
LDL-C goal attainment with ezetimibe plus simvastatin coadministration vs atorvastatin or simvastatin monotherapy in patients at high risk of CHD. MedGenMed (2005) 0.80
Effects of sibutramine in obese female subjects with type 2 diabetes and poor blood glucose control. Diabetes Care (2001) 0.79
Combination-therapy with bedtime nph insulin and sulphonylureas gives similar glycaemic control but lower weight gain than insulin twice daily in patients with type 2 diabetes. Diabetes Metab (2002) 0.77
2nd International Symposium on triglycerides and HDL: metabolic syndrome. Diabetes Care (2005) 0.76
Eighteen-year results in the treatment of early breast carcinoma with mastectomy versus breast conservation therapy: the National Cancer Institute Randomized Trial. Cancer (2003) 2.77
Amphetamine, past and present--a pharmacological and clinical perspective. J Psychopharmacol (2013) 1.22
Twenty-five year results of the national cancer institute randomized breast conservation trial. Breast Cancer Res Treat (2011) 1.01
A preclinical evaluation of the discriminative and reinforcing properties of lisdexamfetamine in comparison to D-amfetamine, methylphenidate and modafinil. Neuropharmacology (2013) 0.97
Methylphenidate and its isomers: their role in the treatment of attention-deficit hyperactivity disorder using a transdermal delivery system. CNS Drugs (2006) 0.96
What is the prognosis for new centrally-acting anti-obesity drugs? Neuropharmacology (2012) 0.88
Early ipsilateral breast tumor recurrences after breast conservation affect survival: an analysis of the National Cancer Institute randomized trial. Int J Radiat Oncol Biol Phys (2005) 0.86
A phase I trial of a potent P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), administered orally in combination with doxorubicin in patients with advanced malignancies. Clin Cancer Res (2002) 0.85
Cochlear implantation in the elderly: results and quality-of-life assessment. Ann Otol Rhinol Laryngol (2002) 0.83
Metabolic consequences of antipsychotic therapy: preclinical and clinical perspectives on diabetes, diabetic ketoacidosis, and obesity. Handb Exp Pharmacol (2012) 0.82
ADHD: current and future therapeutics. Curr Top Behav Neurosci (2012) 0.80
Differences in the neurochemical and behavioural profiles of lisdexamfetamine methylphenidate and modafinil revealed by simultaneous dual-probe microdialysis and locomotor activity measurements in freely-moving rats. J Psychopharmacol (2013) 0.80
The 5-HT6 receptor as a target for developing novel antiobesity drugs. Int Rev Neurobiol (2011) 0.79
Implications of climate change for northern Canada: the physical environment. Ambio (2009) 0.78
The National Trauma Institute: Lessons learned in the funding and conduct of 16 trauma research studies. J Trauma Acute Care Surg (2016) 0.75
Implications of climate change for economic development in northern Canada: energy, resource, and transportation sectors. Ambio (2009) 0.75